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Abstract  
In-vitro biological activities of the free new H4L ( indole-7-thiocarbohydrazone) ligand and its Ni(II), Pd(II) , Pt(II), 
Cu(II), Ag(I), Zn(II) and Cd(II)  complexes are screened against two cancerous cell lines, that revealed significant 
activity only for [Cu2Cl2(H4L)2(PPh3)2]  after 72 h treatment by the highest tested concentrations. The Copper(I) 
complex was characterized by X-ray Crystallography and the NMR spectra, whereas it has been confirmed to have 
momentous cytotoxicity against ovarian, breast cancerous cell lines (Caov-3, MCF-7). The apoptosis-inducing 
properties of the Cu(I) complex have been investigated through fluorescence microscopy visualization, DNA 
fragmentation analysis and propidium iodide flow cytometry. 
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Introduction:  
Cancer is an imperative area of interest in the life sciences as it has been a prime assassin disease throughout 
human history. It is not one disease, but a bulky group of diseases characterized by uncontrolled growth and spread 
of abnormal cells. Heterocyclic molecules are distinguished to play a critical role in health care and pharmaceutical 
drug design [1,2]. In the relevant annual reviews are to be found examples of metal ions in biological systems and 
coordination chemistry for the series. Inorganic chemistry useful in the medical field can be divided into two main 
categories: firstly, as metal ions to a target protein is free or whether the drugs as ligands; and secondly, metal-
based drugs and imaging agents of central metal ion is usually significant of the mechanism of action [3-5]. The 
choice of the coordinated ligand(s) seems to be as vital as the choice of metal(s) because being the integral part of 
biologically active complexes, in addition these organic molecules (ligands) can exert a biological activity of their 
own [6-11]. Purine, thiosemicarbazone, imidazole, benzohydroxamic ligands as nitrogen donor ligands include 
various types of anti-cancer activities of the range of simple copper complexes have been studied when some 
metal-based antitumor drugs in vitro and in vivo studies have demonstrated greater antineoplastic power than 
Cisplatin[12] . Copper complexes are behaved as the most promising option anticancer drugs as cisplatin, when 
this idea supported by a number of research articles describing the synthesis, thus DNA binding and cytotoxic 
activities of many copper complexes [13,14]. There are only few complexes of Copper(I) in the literature, whereas 
they also be evidence for a very sturdy cytotoxic activity against tumor cells in vitro [15,16]. Anticancer activity 
of Cu(I) complex is related to their ability to produce reactive oxygen species (ROS). Copper(I) ions can reduce 
hydrogen peroxide to hydroxyl radical. Copper(II) ions may in turn be reduced to Cu(I) by superoxide anion(O2•-). 
Consequently, it can be terminated that the production of reactive oxygen species such as OH• are driven by the 
Copper, in spite of the form in which it is initially introduced into the body Cu+, or Cu2+ [17,18]. The hydroxyl 
radical (OH•) is supposed to be the main factor causing DNA damage in cells under oxidative stress [19-21]. Hence, 
we emphasis to report the anticancer activity of new Copper(I) indole-7- thiocarbohydrazone complex . 
Cu2+ + O2•– → Cu+ + O2  
Cu+ + H2O2 → Cu2+ + OH• + OH– 
 
Experimental 
The ligand (H4L) and its Cu(I) complex which were prepared and characterized  according to the previously 
described procedure [22]. The ligand(H4L) and its Cu(I) complex were evaluated for their in vitro cytotoxicity 
towards human ovarian adenocarcinoma and breast cancer cell lines (Caov-3, MCF-7) respectively . 
- Cell Culture 
The cell lines (Caov-3, MCF-7) were provided by Department of Pharmacy, Faculty of Medicine, University of 
Malaya. The cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Sigma 
Aldrich) and L-glutamine at 37 °C in a 5% CO2 humidified atmosphere.  
- MTT Cytotoxixity Test  
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was carried out as described by 
Mosmann [23] with some modifications. The cells were seeded into 96-well plates (5000 cells/well) and allowed 
to adhere overnight. Copper complex was pre-dissolved in dimethyl sulfoxide (DMSO) and diluted to the desired 
concentrations (eight concentrations, 0.39-50 µg/mL), such that the final concentrations of DMSO did not exceed 
0.5%. Each cell was treated with the test compound solutions (three wells on a plate for each concentration) for 
24, 48 and 72 h. Treated and untreated cells were inspected qualitatively using an inverted light microscope (100 
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X). Then, 10 µl of MTT (5 mg/mL) was added to each well and the plates were incubated at 37 °C for 4 h. The 
media was then gently aspirated, and 100 µl DMSO was added to dissolve the formazan crystals. The amount of 
formazan product was measured spectrophotometrically at 570 nm using a microplate reader (Power Wave X 340). 
The concentration of the test compound required for 50% inhibition of cell growth (IC50)was determined by 
interpolation of regression analysis.  
- Apoptosis Detection with Fluorescence Microscopy AO/PI Staining Assay 
The cancer cell lines were seeded in a 25 mL culture-flask (1 × 106 cells/mL) and treated with the Copper complex 
at the corresponding IC50 concentrations for 24, 48 and 72 h. The cells were washed with phosphate buffered saline 
(PBS) and suspended in 500 µL of PBS followed by addition of a 1:1 mixture of Acridine orange (AO) 10 µg/ml 
and propidium iodide (PI) 10 µg/ml. A drop of the suspension was placed on a glass slide and covered with a cover 
slip. Images of the cells were taken by a UV-fluorescence microscope within 30 min.  
- DNA-Fragmentation Analysis 
 The cancer cell lines were seeded in a 25 mL culture-flask (1 × 106 cells/mL) and treated with the respective IC50 
concentrations of the test compound for 24, 48 and 72 h (control cells were treated with 0.5% DMSO vehicle). 
The cells were then washed with PBS.The treated and control cells were washed with PBS and harvested. Cellular 
DNA was extracted using the apoptotic DNA ladder detection kit (Chemicon International Inc., Palo Alto, CA, 
USA). The DNA fragments were then separated by a 1.5% agarose gel electrophoresis at 50 V for 3 h.The Gels 
were then stained with ethidium bromide and visualized on a UV-illuminator. 
- Cell cycle analysis 
A flow cytometry analysis was carried out to determine the cell cycle distribution in treated ovarian 
adenocarcinoma (Caov-3) cell line with [Cu2(H4L)2(PPh3)2Cl2] [24]. In brief,  (Caov-3, MCF-7) cell lines (5×104 
cells/ml) were treated with  [Cu2(H4L)2(PPh3)2Cl2] at IC50 concentration for 24, 48 and 72 h. After fixation with 
cold ethanol, cells were washed with PBS and stained with PI (50 µl, 10 mg/ml) for 1 h at 37 ˚C. In addition, 
RNase A (10 mg/ml) was also used to limit the ability of PI to bind only to DNA molecules. The stained cell was 
analyzed for DNA content using flow cytometer (BD FACSCanto TM II). 
 
Results and discussion 
- Structure of the Copper(I) complex 
The reaction of H4L with equimolar amount of CuCl and PPh3 afforded the Cu(I) complex of [Cu2Cl2(H4L)2(PPh3)2] 
(Scheme 1). The crystal structure of the complex is shown in (Figure 1). The thiocarbohydrazone is almost planar 
(r. m. s. deviation = 0.151 Å) and adopts an anti geometry. Two neutral thiocarbohydrazones, acting as µ2-S-donor 
ligands, doubly bridge pairs of the Cu(I) atom into a centrosymmetric dimer. The Cu centers within the Cu2(µ2-S)2 
core are separated by 3.0681(6) Å, which is larger than sum of their van der Waals radii (2.80 Å). One Cl atom 
and one PPh3 group complete a distorted tetrahedral geometry around each metal center, with coordination angles 
being ca. 96-119°.The geometric parameters of the parallelogram and those pertaining to the metal centers are 
compatible with the reported values for similar structures [25-27]. The Cl atom is intramolecularly hydrogen 
bonded to N3, and intermolecularly H-bonded to a methanol solvate molecule. Theoretical calculations on similar 
dinucler Cu(I) structures suggested that the hydrogen bonding between the halogen ligands and the solvent 
molecules plays a crucial role in the formation of S-bridged dimers vs. halogen-bridged or monomeric structures 
[22,25] . 
 
Figure 1 Molecular structure of [Cu2Cl2(H4L)2(PPh3)2] with thermal ellipsoids drawn at the 30% probability level. 
C-bound H atoms and methanol solvent molecules are omitted for clarity. Symmetry code: i = -x+1, -y+1, -z+1.  
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Scheme 1. Synthesis of the Cu(I) complex 
The Cu complex also characterized by 1H , 13C NMR and HSQC spectra in DMSO-d6 that in agreement 
with the crystal structure, indicating the stability of the structure in the solution . The 13C NMR spectrum shows 
an upfield shift of the CS signal (∼3 ppm) from that in the spectrum of H4L. Yield 0.38 g, 53%. Anal. Calc. for 
C74H62Cl2Cu2N12P2S2: C, 61.57; H, 4.33; N, 11.64. Found: C, 61.44; H, 4.08; N, 11.98%. 1H NMR (DMSO-d6): δ 
6.59 (2H, br.s, Ar-H); 6.65 (2H, br.s, Ar-H); 6.99 (2H, br.s, Ar-H); 7.16 (2H, t, J = 6.8 Hz, Ar-H); 7.24-7.48 (34H, 
Ar-H); 7.58 (2H, br.s, Ar-H); 7.69(4H, m, Ar-H); 7.77 (2H, d, J = 7.7 Hz, Ar-H); 8.55 (2H, br.s, HCNN); 8.94 
(2H, br.s, HCNN); 11.30 (2H, s, indole-NH); 11.33 (2H, s, indole-NH); 12.32 (2H, s, NNH); 12.55 (2H, s, NNH ) 
ppm. 13C NMR (DMSO-d6): δ 102.86, 116.82, 117.92, 119.75, 119.84, 123.96, 124.14, 124.70, 126.44, 126.96, 
127.14, 128.75-129.37, 130.48, 131.57, 133.71-133.96 (Ar); 149.89, 150.29 (HCNN); 172.43 (CS) ppm. 
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- Cytotoxicity assay for Cu(I) complex 
(Table1) lists the IC50 values of the Copper(I)  complex after treating the (Caov-3, MCF-7) cancer cell lines for 
24, 48 and 72 h. Based on outcomes that, the IC50 values were (13, 25.75) µM for 24 h treatment; however, the 
value declined, in case of prolonged treatment, where, IC50 values were (10, 4.25) µM for 48 h treatment, and 
further dropped to (4, 2.5) µM for 72 h treatment; which obviously signifies that, the prolonged treatment 
considerably decreased the IC50 values, and elevated the toxic activity. For the purpose of comparability, ovarian 
adenocarcinoma and breast cancer cell lines were also treated with cisplatin a clinical anticancer drug (Figure 5, 
Figure 6 ), and the results presented in (Table1) that [Cu2(H4L)2(PPh3)2Cl2] revealed higher cytotoxicity than 
cisplatin against the (Caov-3, MCF-7) cancer cell lines . 
Table 1  IC50 (µM) values of [Cu2(H4L)2(PPh3)2Cl2] and cisplatin at different time (24, 48 and 72) h 
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- Apoptosis assay 
Apoptosis initiation is an anti-proliferative mechanism by which the cancer cells go through programmed death. 
Cells undergoing apoptosis are characterized by morphological and biochemical changes including cell shrinkage, 
chromatin condensation and DNA fragmentation. Based on the results of the in vitro cytotoxicity assay 
for [Cu2(H4L)2(PPh3)2Cl2], it was considered valuable to explore the apoptotic properties of the compound. 
Apoptosis in the ovarian adenocarcinoma (Caov-3) and breast (MCF-7) cancer cell lines were screened through 
fluorescence microscopy visualization and DNA fragmentation analysis and propidium iodide flow cytometry.  
- Fluorescence microscopy visualization 
Apoptotic cells display increased plasma membrane permeability to certain fluorescent dyes. Acridine orange 
(AO)/propidium iodide (PI) is a fluorochrome mixture for nuclear staining which permits uniqueness between 
viable, apoptotic and necrotic cells. In this work, the ovarian adenocarcinoma (Caov-3) plus breast cancer (MCF-
7) were subjected to AO/PI staining after treatment with respective IC50 concentrations of [Cu2(H4L)2(PPh3)2Cl2] 
for 24, 48 and 72 h. Fluorescence microscopy exposes  that in the (Caov-3, MCF-7) cancer cell lines the Copper 
complex encouraged cell death fundamentally via apoptosis especially at 72h when the apoptotic cell 
clearly observed (Figure 7, Figure 8). 
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- DNA Fragmentation analysis  
The degeneration of nuclear DNA into nucleosomal units is a biochemical feature of apoptosis. To evaluate the 
apoptotic DNA fragmentation in the cancer cells, the ovarian and breast cancer cell lines were incubated with the 
correspond IC50 value of [Cu2(H4L)2(PPh3)2Cl2]  for 48 and 72 h. The cells were then lysed, the nuclear DNA was 
extracted, and subjected to gel electrophoresis. Inspection of the electrophoretic profiles discovered a ladder 
formation detected only at 72h at both of ovarian and breast cancer cells (fragments range from 400 to 1000 bp), 
which signify the incidence of apoptosis (Figure 9, Figure 10). 
- Cell cycle analysis  
The DNA content of cells duplicates during the S phase, therefore cells in the G0 and G1 phases (before the S phase) 
have unreplicated DNA, while those in the G2 and M phases (after the S phase) have replicated DNA. Analysis of 
cell cycles by flow cytometry enables to distinguish and quantify the cells in different phases of the cell cycle. On 
the flow cytometry DNA histograms cells with degraded and thus hypodiploid DNA are represented in so-called 
“sub-G0/G1” peaks therefore, sub-G0/G1 is a specific marker of cell death by apoptosis [28,29]. Flow cytometry 
analysis of the Caov-3, MCF-7 cancer cell lines after treatments with respective IC50 concentrations of the 
[Cu2(H4L)2(PPh3)2Cl2] for 24, 48 and 72 h was carried out (Figure11, Figure12). Moreover, the histogram of Caov-
3 illustrates gradual increases in the populations of sub-G0/G1 phase during the incubation periods whereas the 
histogram of MCF-7 illustrates gradual increases in the populations of G2/M phase In general, flow cytometry 
suggests the induction of apoptosis by the Copper(I)  complex in the Caov-3 cancer cell through G0/G1 phase while 
through Sub-G0/G1 phase for MCF-7 cell cycle arrest. 
 
Conclusion  
As it was presented in this article, Copper(I) coordination complex has notable and cancer-selective cytotoxicity 
against the Caov-3, MCF-7 cancer cell lines as inferred from the MTT-based IC50 values and different apoptotic 
assay methods in consequence, Intensive research possibly will enable to apply it as anticancer drug. 
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